ALK (Anaplastic lymphoma kinase), ATM (ATM serine/threonine kinase), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), EGFR (Epidermal growth factor receptor)
See More ...
ALK (Anaplastic lymphoma kinase), ATM (ATM serine/threonine kinase), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), EGFR (Epidermal growth factor receptor), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), HER-2 (Human epidermal growth factor receptor 2), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), JAK1 (Janus Kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KIT (KIT proto-oncogene, receptor tyrosine kinase), MET (MET proto-oncogene, receptor tyrosine kinase), MSH2 (MutS Homolog 2), MSH6 (MutS homolog 6), NTRK (Neurotrophic receptor tyrosine kinase), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), PTEN (Phosphatase and tensin homolog), RB1 (RB Transcriptional Corepressor 1), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TERT (Telomerase Reverse Transcriptase), TP53 (Tumor protein P53)